Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
VIREAD (tenofovir disoproxil fumarate) is an oral nucleotide reverse transcriptase inhibitor approved for HIV-1 infection and chronic hepatitis B. It works by inhibiting viral reverse transcriptase, preventing viral replication in infected patients. This small-molecule antiviral is a foundational component of modern combination antiretroviral therapy.
Peak-stage product with established market presence; brand team focused on market maintenance and managed competition rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)
A Study of Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) and MK-8527 in Healthy Participants
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)
Switching From Tenofovir Disoproxil Fumarate to Besifovir Dipivoxil Maleate
Worked on VIREAD at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on VIREAD offers stability in a mature, established therapeutic franchise with deep market knowledge and predictable business dynamics. However, career growth is constrained by flat-to-declining volumes, making this a consolidation-phase role better suited to specialists in market defense, reimbursement strategy, and operational excellence rather than high-growth brand building.